无进展生存期在癌症II期临床试验中作为有效终点的应用。 - Suppr

Suppr

超能文献

Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.

作者信息

Markman Maurie

机构信息

University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Curr Oncol Rep. 2007 May;9(3):159-60. doi: 10.1007/s11912-007-0015-2.

DOI:10.1007/s11912-007-0015-2

PMID:17430685

Abstract

摘要

相似文献

Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.无进展生存期在癌症II期临床试验中作为有效终点的应用。

Curr Oncol Rep. 2007 May;9(3):159-60. doi: 10.1007/s11912-007-0015-2.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?2期试验中肿瘤大小的早期平均变化：有效终点还是虚假承诺？

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

Mixed response and time-to-event endpoints for multistage single-arm phase II design.多阶段单臂II期设计的混合反应和事件发生时间终点

Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.

Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

General and statistical hierarchy of appropriate biologic endpoints.合适生物学终点的一般和统计学层次结构。

Oncology (Williston Park). 2006 May;20(6 Suppl 5):5-9.

Perils of the Pathologic Complete Response.病理完全缓解的风险

J Clin Oncol. 2016 Nov 20;34(33):3959-3962. doi: 10.1200/JCO.2016.68.1718. Epub 2016 Oct 31.

Performance of adaptive designs for single-armed phase II oncology trials.单臂II期肿瘤学试验适应性设计的性能

J Biopharm Stat. 2015;25(3):602-15. doi: 10.1080/10543406.2014.920863.

Multinomial phase II trial designs.多项II期试验设计。

J Clin Oncol. 2002 Jan 15;20(2):599.

Assessing temporal agreement between central and local progression-free survival times.评估中心和局部无进展生存时间之间的时间一致性。

Stat Med. 2015 Feb 28;34(5):844-58. doi: 10.1002/sim.6371. Epub 2014 Nov 13.

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.评估癌症治疗药物的 II 期临床试验设计：美国国家癌症研究所试验药物指导委员会临床试验设计工作组的共识建议。

Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9.

引用本文的文献

Using short-term response information to facilitate adaptive randomization for survival clinical trials.利用短期反应信息促进生存临床试验的适应性随机分组。

Stat Med. 2009 May 30;28(12):1680-9. doi: 10.1002/sim.3578.

本文引用的文献

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.无进展生存率作为II期癌症临床试验的主要终点：在间皮瘤中的应用——欧洲癌症研究与治疗组织肺癌小组

J Clin Oncol. 2006 Jul 1;24(19):3007-12. doi: 10.1200/JCO.2005.05.1359.

Viewing ovarian cancer as a "chronic disease": what exactly does this mean?将卵巢癌视为“慢性病”：这究竟意味着什么？

Gynecol Oncol. 2006 Feb;100(2):229-30. doi: 10.1016/j.ygyno.2005.08.043. Epub 2005 Oct 14.

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.使用相同化疗方案的II期研究与后续随机对照研究结果的比较。

J Clin Oncol. 2005 Oct 1;23(28):6982-91. doi: 10.1200/JCO.2005.06.679.

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.吉非替尼用于复发性或持续性卵巢癌或原发性腹膜癌患者的II期研究及表皮生长因子受体突变和免疫组化表达评估：一项妇科肿瘤学组研究

Clin Cancer Res. 2005 Aug 1;11(15):5539-48. doi: 10.1158/1078-0432.CCR-05-0462.

Is patient travel distance associated with survival on phase II clinical trials in oncology?在肿瘤学的II期临床试验中，患者的就诊距离与生存率有关吗？

J Natl Cancer Inst. 2003 Sep 17;95(18):1370-5. doi: 10.1093/jnci/djg035.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.一项关于抗血管内皮生长因子抗体贝伐单抗用于转移性肾癌的随机试验。

N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.实体瘤治疗反应评估新指南。欧洲癌症研究与治疗组织、美国国立癌症研究所、加拿大国立癌症研究所。

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.

The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.区分癌症治疗中的“临床判断”与临床试验中的“选择偏倚”的重要性。

J Cancer Res Clin Oncol. 1996;122(10):573-4. doi: 10.1007/BF01221187.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验